Are dual ARVs the new frontier in a maturing HIV market?Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and Share XAre dual ARVs the new frontier in a maturing HIV market?https://pharmaphorum.com/sales-marketing/are-dual-arvs-the-new-frontier-in-a-maturing-hiv-market/
J&J builds case for HIV vaccine ahead of pivotal trial readoutJohnson & Johnson has moved a step closer to the goal of developing a vaccine that can help Share XJ&J builds case for HIV vaccine ahead of pivotal trial readouthttps://pharmaphorum.com/news/jj-builds-case-hiv-vaccine/
ViiV redeems voucher for fast FDA review of HIV combinationViiV Healthcare has applied for a fast US review of its single-tablet, two drug HIV drug regimen of Share XViiV redeems voucher for fast FDA review of HIV combinationhttps://pharmaphorum.com/news/viiv-redeems-voucher-for-fast-fda-review-of-hiv-combination/
MPs call for NHS funding for HIV prevention drugLeading UK politicians have called for an HIV prevention drug to be made available across the NHS, after Share XMPs call for NHS funding for HIV prevention drughttps://pharmaphorum.com/news/mps-call-for-nhs-funding-for-hiv-truvada/
Truvada ruling could allow cheap HIV prevention in the UKCheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk of people Share XTruvada ruling could allow cheap HIV prevention in the UKhttps://pharmaphorum.com/news/truvada-ruling-could-allow-cheap-hiv-prevention-in-the-uk/
FDA approves Merck’s Delstrigo and Pifeltro for HIV treatmentMerck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) Share XFDA approves Merck’s Delstrigo and Pifeltro for HIV treatmenthttps://pharmaphorum.com/news/fda-approves-mercks-hiv-treatment/
HIV drug cuts viral load, boosts immunity in Yale studyA Yale University study has found ibalizumab reduced viral replication and increased the count of immune cells in Share XHIV drug cuts viral load, boosts immunity in Yale studyhttps://pharmaphorum.com/news/ibalizumab-cuts-hiv-viral-load/
GSK’s monthly HIV treatment breakthroughGlaxoSmithKline has seen positive clinical results from the phase 3 study of its once-monthly injectable HIV treatment, stepping Share XGSK’s monthly HIV treatment breakthroughhttps://pharmaphorum.com/news/gsks-monthly-hiv-treatment-breakthrough/
ViiV prepares another two-drug HIV filingViiV Healthcare says it is on course to change standard care in HIV treatment by providing another combination Share XViiV prepares another two-drug HIV filinghttps://pharmaphorum.com/news/viiv-prepares-another-two-drug-hiv-filing/
